University at Buffalo - The State University of New York
Skip to Content
Steven                         Hochwald

Steven N. Hochwald MD

Department of Surgery

Chief of Gastrointestinal Surgery Vice Chair of Department of Surgical Oncology

Professional Summary:

I have been Chief of Gastrointestinal Surgery and Professor of Oncology at Roswell Park Cancer Institute since April 2012. I did my residency at the NYU Medical Center Department of Surgery and both research and clinical fellowships at Memorial Sloan Kettering Cancer Center and I am a graduate of Johns Hopkins University with a MD from New York University School of Medicine.

My research focuses on technical advances in minimally invasive esophageal and GI surgeries and developing new targets and agents for treatment of pancreatic and other GI cancers. I lead a funded laboratory program which focuses on glucose promotion of histidine signaling to drive cancer progression in the absence of growth factor stimulation. The goal is to target histidine signaling as novel therapy in GI cancer.

Education and Training:
  • MBA, Business, University at Buffalo (2017)
  • Residency, New York University Medical Center (1997)
  • Residency, New York University Medical Center (1996)
  • Fellowship, Surgical Oncology, Memorial Sloan-Kettering Cancer Center (1995)
  • Internship, Categorical General Surgery, New York University Medical Center (1991)
  • MD, Medicine, New York University School of Medicine (1990)
  • BA, John Hopkins University (1986)
Awards and Honors:
  • Best Doctors in America (2017)
  • US News Top Doctor (2017)
  • Buffalo Spree Best Docs (2017)
  • 2016 Top Oncologist, International Association of Oncologists (2017)
  • International Business Honor Society:Beta Gamma Sigma (2017)
  • Surgical Oncology Fellows Teaching Award (2014)
  • Comission on Cancer (2008)
  • Cancer Liaison Physician Outstanding Performance Award (2007)
  • Dept. of Surgery Research Career Development Award (2005)
  • Lester Dragstedt Physician-Scientist Award (2002)
  • Lester Dragstedt Physician-Scientist Award (2001)
  • SSAT/Ross Laboratory presentation (1999)
  • SSAT/Ross Laboratory presentation (1997)
  • New York University Housestaff award for Scholarship (1996)
  • NCI National Research Service Award (1995)
  • Alpha Epsilon Delta Premedical Honor Society (1985)
  • National Westinghouse Science Competition (1981)

Grants and Sponsored Research:
  • February 2013–January 2017
    Esophageal Cancer Research Fund
    Roswell Park Cancer Institute
    Role: Principal Investigator
  • January 2006–December 2016
    Phosphohistidine signaling in glycolytic metabolite control of gastric tumorigenesis
    Roswell Park Alliance Foundation
    Role: Principal Investigator
  • July 2010–May 2015
    Design, synthesis and evaluation of novel selective inhibitors of FAK and IGF-1R function in pancreatic cancer.
    Bankhead Coley Cancer Research Program
    Role: Principal Investigator
  • January 2012–December 2012
    Novel therapeutic targets and approaches in pancreatic cancer
    University of Florida Shands Cancer Center
    Role: Principal Investigator
  • July 2006–June 2011
    FAK and IGF-1R interactions in pancreatic cancer survival
    Role: Principal Investigator
  • March 2009–February 2010
    Modulating radiation response in pancreatic cancer through targeting the FAK/IGF-1R pathways.
    Moffitt-UF Collaborative grant
    Role: Principal Investigator
  • March 2009–February 2010
    Novel agents that target FAK and IGF-1R binding in pancreatic cancer
    Moffitt-UF Collaborative grant
    Role: Principal Investigator
  • February 2009–January 2010
    Targeting FAK and VEGFR-3 in melanoma
    Bankhead Coley Research Foundation
    Role: Principal Investigator
  • November 2005–November 2006
    A single center prospective randomized trial of Epoetin alpha in patients undergoing major abdominal operation for malignancy.
    Ortho Biotech
    Role: Co-Principal Investigator
  • July 2005–June 2006
    Anti-neoplastic efficacy of FAK and/or IGF-1R tyrosine kinase inhibition in human pancreatic cancer xenografts
    University of Florida Department of Surgery Career Development Award
    Role: Principal Investigator
  • July 2003–June 2005
    Alternative estrogen therapy for colon cancer prevention
    NCI R21CA098741-01
    Role: Co-Investigator
  • September 2001–December 2004
    A phase II trial of neoadjuvant irinotecan and docetaxel chemotherapy followed by surgery in patients with gastric cancer
    Aventis Pharmaceuticals
    Role: Principal Investigator
  • July 2001–December 2004
    Role of Nuclear Factor kB in the chemotherapy and radioresistance of gastrointestinal cancer.
    Florida Biomedical Research Program
    Role: Principal Investigator
See all (3 more)
  • "Jejunostomy tube and method" (2015)
  • "Kinase protein binding inhibitors" Licensed in 2010 (2009)

Journal Articles:
See all (24 more)
Evaluative Studies and Case Reports:
See all (1 more)

Professional Memberships:
  • American Surgical Association; Active Member
  • Surgical Biology Club 1; Active Member
  • Southern Surgical Association; Active Member
  • Society for Surgery of the Alimentary Tract; Active Member
  • American College of Surgeons; Fellow
  • Society of Surgical Oncology; Member
  • American Society of Clinical Oncology; Member
  • American Society of Clinical Oncology; Member
  • Association for Academic Surgery; Member
  • American Hepato-Pancreato-Biliary Association; Member
  • American Association of Cancer Research; Member
  • Society of University Surgeons; Active Member
  • North America Neuroendocrine Tumor Society; Member
See all (3 more)

School News:
In the Media:

Clinical Specialties:
Clinical Offices:
Insurance Accepted:

Contact Information

Roswell Park Cancer Institute
Elm and Carlton Street
Buffalo, NY 14263
Phone: 719-845-2300
Fax: N/A

Log in to Update Your Profile